Cipla is one of India’s leading pharma company with exposure to the US generics market and South Africa, where it is the third largest player. Over the years, Cipla has developed a front end presence in the US as against its earlier strategy of operating through partnerships. Recent acquisitions and new launches in US for inhalers should drive growth. A notable aspect of Cipla is its strong regulatory compliance with least issues with US FDA as compared to its peer group. We have an over weight rating on the stock due to long term focus on profitable growth from differentiated products and impressive volumes in the domestic formulation division. Valuations are fair but there could be earnings volatility. Impact of Covid-19 pandemic has been restricted due to essential nature of products – 12-08-2021 Price: 905.05 Rating: Over Weight Recommendation: Buy
Elixir Equities Private Limited (hereinafter referred to as “EEPL”) is a registered Member of National Stock Exchange of India Limited, BSE Limited and Depository Participant of the Central Depository Services Ltd. It is also a SEBI registered Portfolio Manager. We have been granted certificate of Registration as a Research Analyst with SEBI. Registration no. is INA000004787 for the period of 5 (Five) Years from 19th May, 2017.
EEPL or its associates including its relatives/analyst do not hold any financial interest/beneficial ownership of more than 1% in any of the companies covered by us. However, we or our clients, relatives and associates may have an investment / trading / arbitrage / market making (informal) position of less than 1% financial interest/beneficial ownership in the companies covered by us and recommended through this portal.
We, our associates/analyst have not received any compensation from any of the companies covered by us during the past twelve months. Neither EEPL nor its analyst has served as an officer, director or employee of any of the companies covered by us. We do provide any service to any of the companies covered by us. The views expressed herein are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision.
The information and opinions in this report have been prepared by EEPL and are subject to change without any notice.
Our views and opinions are based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. Nothing in this website / portal / application constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances.
The securities discussed and opinions expressed may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This service may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. EEPL accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this website / portal / app.
We submit that no material disciplinary action has been taken on EEPL by any Regulatory Authority.
This website/ portal / service/ app is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject EEPL and affiliates to any registration or licensing requirement within such jurisdiction.
EEPL endeavours to provide objective opinions and recommendations.
We assign Buy, Hold and Sell ratings on the securities covered by us.
Our rationale for these ratings has Super, Over, Neutral and Nil Weight ratings these securities as well. These Super, Over, Neutral and Nil Weight ratings serve as a guide to the quantum / weightage of that security which may be held in your portfolio.
The ratings are for long term investing for a minimum of three years unless specified.